Episode

Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

Podcast

Decera Clinical Education Oncology Podcast

Published

Apr 14, 2026

Duration seconds

2686

Processing state

not_requested

Canonical source

https://oncologypodcast.simplecast.com/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer-pCssUC_H

Audio

https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/3cf5ff3c-6ce7-45dd-978c-9331c8089697/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=3cf5ff3c-6ce7-45dd-978c-9331c8089697&feed=GlfUTtJq

JSON

/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer

Markdown

/podcast/decera-clinical-education-oncology-podcast-1302999/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer.md

Actions

• POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer/transcription-requests
  Idempotently request low-priority transcript generation for this episode.
• GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer.md
  Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, experts discuss practical, patient-centered strategies for CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on adverse event monitoring and management, dose modifications, adherence support, and preventing early discontinuation. The discussion also highlights real-world approaches to counseling, multidisciplinary coordination, and helping patients stay on therapy long term.